{
    "clinical_study": {
        "@rank": "80709", 
        "arm_group": {
            "arm_group_label": "Palifermin", 
            "arm_group_type": "Experimental", 
            "description": "Palifermin 60 micrograms/kg/day IV for 3 consecutive days"
        }, 
        "brief_summary": {
            "textblock": "To test the ability of palifermin (a recombinant human keratinocyte growth factor) to\n      decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis\n      and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is\n      extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal\n      tract, respiratory and genitourinary systems."
        }, 
        "brief_title": "Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis", 
        "condition": [
            "Toxic Epidermal Necrolysis", 
            "Stevens-Johnson Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Epidermal Necrolysis, Toxic", 
                "Staphylococcal Scalded Skin Syndrome", 
                "Stevens-Johnson Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in\n             more advanced disease necrosis of the entire epidermis\n\n          -  Epidermal detachment or erythematous to purpuric macules involving more than 10% of\n             body surface area in addition to involvement of the oropharynx; there may be further\n             involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract,\n             respiratory and genitourinary epithelia\n\n          -  Age of 18 years old or older\n\n          -  The patient is expected to survive longer than 48 hours\n\n        Exclusion Criteria:\n\n          -  Skin detachment above 90% of the body surface area\n\n          -  Skin detachment has not progressed during the previous 48 hours\n\n          -  A positive serum pregnancy test\n\n          -  Age < 18 years old\n\n          -  Known hematologic or solid organ malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037347", 
            "org_study_id": "0901004673", 
            "secondary_id": "020901"
        }, 
        "intervention": {
            "arm_group_label": "Palifermin", 
            "intervention_name": "Palifermin", 
            "intervention_type": "Drug", 
            "other_name": "Kepivance"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bridgeport", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06610"
                    }, 
                    "name": "Bridgeport Hospital"
                }, 
                "investigator": {
                    "last_name": "Alisa Savetamal, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale-New Haven Hospital"
                }, 
                "investigator": {
                    "last_name": "Brett A King, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Palifermin Treatment of Toxic Epidermal Necrolysis", 
        "overall_contact": {
            "email": "brett.king@yale.edu", 
            "last_name": "Brett A King, MD, PhD", 
            "phone": "203-737-4825"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time-to-cutaneous re-epithelialization", 
            "safety_issue": "No", 
            "time_frame": "The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037347"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Brett King", 
            "investigator_title": "Assistant Professor of Dermatology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time-to-mucosal re-epithelialization", 
                "safety_issue": "No", 
                "time_frame": "The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days"
            }, 
            {
                "measure": "Time-to-cessation of epidermal necrosis", 
                "safety_issue": "No", 
                "time_frame": "The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "Swedish Orphan Biovitrum", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Brett King", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}